Cargando…

Chemotherapy-elicited upregulation of NKG2D and DNAM-1 ligands as a therapeutic target in multiple myeloma

Malignant cells constitutively express Natural killer group 2, member D (NKG2D) or DNAX Accessory Molecule-1 (DNAM-1) ligands, yet they are often unable to trigger a robust cytotoxic cell response. It may be therapeutically useful to implement strategies aimed at increasing the density of NKG2D and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soriani, Alessandra, Fionda, Cinzia, Ricci, Biancamaria, Iannitto, Maria Luisa, Cippitelli, Marco, Santoni, Angela
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Landes Bioscience 2013
Materias:	Author's View
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3912005/ https://www.ncbi.nlm.nih.gov/pubmed/24498552 http://dx.doi.org/10.4161/onci.26663

Ejemplares similares

NKG2D and DNAM-1 Ligands: Molecular Targets for NK Cell-Mediated Immunotherapeutic Intervention in Multiple Myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

Nitric oxide donors increase PVR/CD155 DNAM-1 ligand expression in multiple myeloma cells: role of DNA damage response activation
por: Fionda, Cinzia, et al.
Publicado: (2015)

The DNA Damage Response: A Common Pathway in the Regulation of NKG2D and DNAM-1 Ligand Expression in Normal, Infected, and Cancer Cells
por: Cerboni, Cristina, et al.
Publicado: (2014)

NKG2D and Its Ligands: “One for All, All for One”
por: Zingoni, Alessandra, et al.
Publicado: (2018)

Immunomodulatory effect of NEDD8-activating enzyme inhibition in Multiple Myeloma: upregulation of NKG2D ligands and sensitization to Natural Killer cell recognition
por: Petillo, Sara, et al.
Publicado: (2021)

NKG2D ligands link oncogenic RAS to innate immunity
por: Ho, Samantha S.W., et al.
Publicado: (2013)

STING-dependent cytosolic DNA sensor pathways regulate NKG2D ligand expression
por: Le Bert, Nina, et al.
Publicado: (2014)

Tumor suppressors control ULBP2, an innate surface ligand of the lymphocyte immune receptor NKG2D
por: Heinemann, Anja, et al.
Publicado: (2012)

Regulation of NKG2D signaling during the epithelial-to-mesenchymal transition
por: López-Soto, Alejandro, et al.
Publicado: (2013)

Natural Killer Cell Response to Chemotherapy-Stressed Cancer Cells: Role in Tumor Immunosurveillance
por: Zingoni, Alessandra, et al.
Publicado: (2017)

Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay
por: Abruzzese, Maria Pia, et al.
Publicado: (2016)

How Mucosal Epithelia Deal with Stress: Role of NKG2D/NKG2D Ligands during Inflammation
por: Antonangeli, Fabrizio, et al.
Publicado: (2017)

NKG2D and DNAM-1 activating receptors and their ligands in NK-T cell interactions: role in the NK cell-mediated negative regulation of T cell responses
por: Zingoni, Alessandra, et al.
Publicado: (2013)

Cross-Dressing of Multiple Myeloma Cells Mediated by Extracellular Vesicles Conveying MIC and ULBP Ligands Promotes NK Cell Killing
por: Vulpis, Elisabetta, et al.
Publicado: (2023)

Metastamir-mediated immune evasion: miR-10b downregulates the stress-induced molecule MICB, hence avoid recognition by NKG2D receptor
por: Tsukerman, Pinchas, et al.
Publicado: (2013)

Altered expression of ligands for the NKG2D and DNAM-1 activating receptors during HIV-1 infection
por: Vassena, Lia, et al.
Publicado: (2013)

Low-dose bortezomib increases the expression of NKG2D and DNAM-1 ligands and enhances induced NK and γδ T cell-mediated lysis in multiple myeloma
por: Niu, Chao, et al.
Publicado: (2016)

An anticancer therapy-elicited immunosurveillance system that eliminates tetraploid cells
por: Senovilla, Laura, et al.
Publicado: (2013)

Epigenetic remodeling combined with photodynamic therapy elicits anticancer immune responses
por: Wachowska, Malgorzata, et al.
Publicado: (2014)

Poxviral-based vaccine elicits immunologic responses in prostate cancer patients
por: Madan, Ravi A, et al.
Publicado: (2014)

DKK1 as a novel target for myeloma immunotherapy
por: Qian, Jianfei, et al.
Publicado: (2012)

The TLR7 agonist imiquimod as an adjuvant for radiotherapy-elicited in situ vaccination against breast cancer
por: Demaria, Sandra, et al.
Publicado: (2013)

PARP1 inhibition elicits immune responses against non-small cell lung cancer
por: Juncheng, Pan, et al.
Publicado: (2022)

The IMiDs targets IKZF-1/3 and IRF4 as novel negative regulators of NK cell-activating ligands expression in multiple myeloma
por: Fionda, Cinzia, et al.
Publicado: (2015)

Contribution of regulatory T cells to immunosuppression and disease progression in multiple myeloma patients
por: Raja, Karthick Raja Muthu, et al.
Publicado: (2013)

Macrophages increase the resistance of pancreatic adenocarcinoma cells to gemcitabine by upregulating cytidine deaminase
por: Amit, Moran, et al.
Publicado: (2013)

Under one roof: The bone marrow survival niche for multiple myeloma and normal plasma cells
por: Nair, Jayakumar R., et al.
Publicado: (2012)

Trogocytosis generates acquired regulatory T cells adding further complexity to the dysfunctional immune response in multiple myeloma
por: Brown, Ross, et al.
Publicado: (2012)

Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands
por: Chew, Valerie, et al.
Publicado: (2013)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Predicting responses to chemotherapy in the context that matters - the patient
por: Moreno-Gonzalez, Alicia, et al.
Publicado: (2015)

Targeting endosomal pH for cancer chemotherapy
por: Lucien, Fabrice, et al.
Publicado: (2018)

Membrane-bound KIT ligand-targeting DNA vaccination inhibits mammary tumor growth
por: Dentelli, Patrizia, et al.
Publicado: (2014)

Dendritic cells matured in the presence of TLR ligands overcome the immunosuppressive functions of regulatory T cells
por: Berk, Erik, et al.
Publicado: (2014)

GAS6/TAM signaling pathway controls MICA expression in multiple myeloma cells
por: Kosta, Andrea, et al.
Publicado: (2022)

Bone Marrow Stromal Cell-Derived IL-8 Upregulates PVR Expression on Multiple Myeloma Cells via NF-kB Transcription Factor
por: Mekhloufi, Abdelilah, et al.
Publicado: (2020)

Co-stimulatory tumor necrosis factor ligands as adjuvants for the development of subunit-based anticancer vaccines
por: Shirwan, Haval, et al.
Publicado: (2013)

NEDD8-activating enzyme inhibition potentiates the anti-myeloma activity of natural killer cells
por: Petillo, Sara, et al.
Publicado: (2023)

Hitting More Birds with a Stone: Impact of TGF-β on ILC Activity in Cancer
por: Fionda, Cinzia, et al.
Publicado: (2020)

Chemokines and chemokine receptors required for optimal responses to anticancer chemotherapy
por: Ma, Yuting, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_m9qdi3mpef741sr8fs31r5egql